TrialJapanese journal of clinical oncology2013

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.

Tomohiro Nishina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.